3 completed, 3 unknown, 1 terminated, 1 withdrawn. 6 Phase 1, 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 3, Unknown 3 |
| Phase 3 | 2 | Terminated 1, Withdrawn 1 |
| Phase 2 | 1 | Completed 1 |
Follow itolizumab: new trials by email Literature Review of itolizumab trials Research Report on itolizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Preliminary Clinical Activity of Itolizumab in ARDS Itolizumab - Acute Respiratory Distress Syndrome | Phase 1 | Unknown | Biotech Pharmaceutical Co., Ltd. | 38 | 2023-12-31 | 2023-08-07 |
| Safety and Preliminary Clinical Activity of Itolizumab in Dermatomyositis Itolizumab - Dermatomyositis, Adult Type | Phase 1 | Unknown | Biotech Pharmaceutical Co., Ltd. | 44 | 2023-12-30 | 2023-08-14 |
| Safety and Clinical Activity of Itolizumab in aGVHD Itolizumab, Methylprednisolone - Acute Graft Versus Host Disease | Phase 1 | Unknown | Biotech Pharmaceutical Co., Ltd. | 44 | 2023-05-19 | 2023-05-25 |
| A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR) Itolizumab, EQ001 Placebo - Graft Versus Host Disease, GVHD | Phase 3 | Terminated | Equillium | 158 | 2022-04-29 | 2025-06-17 |
| A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19 EQ001, EQ001 Placebo - Coronavirus | Phase 3 | Withdrawn | Biocon Limited | 2020-11-01 | 2026-05-12 | |
| Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis Itolizumab [Bmab 600] - Lupus Erythematosus, Lupus Nephritis | Phase 1 | Completed | Biocon Limited | 52 | 2019-10-01 | 2026-06-04 |
| A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD EQ001, EQ001 Placebo - Acute-graft-versus-host Disease, aGVHD | Phase 1 / Phase 2 | Completed | Biocon Limited | 30 | 2019-07-15 | 2026-06-11 |
| A Study of Itolizumab (EQ001) to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity in Uncontrolled Asthma EQ001, EQ001 Placebo - Asthma | Phase 1 | Completed | Biocon Limited | 18 | 2019-06-20 | 2026-06-02 |
Graft vs Host Disease (2) · Asthma (1) · COVID-19 (1) · Coronavirus Infections (1) · Dermatomyositis (1) · Lupus Erythematosus, Systemic (1) · Lupus Nephritis (1) · Respiratory Distress Syndrome (1)
Biocon Limited (4) · Biotech Pharmaceutical Co., Ltd. (3) · Equillium (1)
United States (3) · Australia (2) · New Zealand (2) · Belgium (1) · Canada (1) · China (1) · Colombia (1) · France (1) · Germany (1) · India (1) · Israel (1) · Italy (1) · Poland (1) · Portugal (1) · South Korea (1)
Bin Du (1) · Erlie Jiang (1) · Huadong Zhu (1) · Jo A Douglass, MD (1) · Joel Rothman (1) · Kenneth Kalunian, MD (1) · Maple Fung, MD (1) · Rui Chen (1) · Xiaofeng Zeng (1)